Before the middle of the 20th century, the arrival of summer brought a shadow of fear across much of the world. Poliomyelitis, or polio, was a highly infectious viral disease that struck primarily children, leaving thousands paralyzed or struggling to breathe in the metal coffins known as iron lungs. Outbreaks shut down towns, parents kept their children away from pools and theaters, and the medical community was largely powerless. This era of dread was transformed by one of the greatest scientific achievements in human history: the development of the first polio vaccines. The work of Jonas Salk and Albert Sabin did not just tame a terrifying disease; they provided the blueprint for modern global health campaigns and brought humanity to the brink of eradicating a second major disease.

Understanding the Scourge of Polio

Polio is an ancient disease, with depictions of withered limbs found in Egyptian art. However, it was not until the late 19th and early 20th centuries that it transformed into a global epidemic. Paradoxically, improved sanitation in industrialized nations may have contributed to this shift. In areas with poor hygiene, infants were exposed to the virus early, often gaining immunity while still protected by maternal antibodies. As sanitation improved, exposure was delayed, leaving older children and adults vulnerable to the more severe forms of the disease when they eventually encountered it.

The "Summer Plague"

The peak of the polio epidemic in the United States and Europe occurred in the 1940s and 1950s. The 1916 New York City outbreak alone killed over 2,000 people and paralyzed thousands more. The disease became hyper-endemic in the summer months, earning its nickname. The most famous victim was probably U.S. President Franklin D. Roosevelt, who was diagnosed with polio in 1921 at the age of 39. FDR’s personal struggle with the disease led directly to the founding of the National Foundation for Infantile Paralysis (NFIP) in 1938, which launched the "March of Dimes" fundraising campaign. This organization was unique: it was a grassroots movement that collected millions of dimes from ordinary citizens, funding the very research that would eventually develop the vaccines.

Scientific Barriers to a Vaccine

Before a vaccine could be created, scientists had to understand the enemy. The polio virus is a small, simple RNA virus, but it had complex biological characteristics. A major breakthrough occurred in 1949 when John Enders, Thomas Weller, and Frederick Robbins successfully grew the poliovirus in human tissue cultures in a lab. This feat, which won them the Nobel Prize, was a turning point. It allowed researchers to grow large quantities of the virus and, importantly, to study it in a controlled environment. Another critical step was identifying the three distinct serotypes of the virus—Brunhilde, Lansing, and Leon—which was largely accomplished by scientists at the NFIP’s typing program.

Jonas Salk and the Inactivated Polio Vaccine (IPV)

Jonas Salk, a brilliant and ambitious virologist, had already gained acclaim for developing an influenza vaccine using a "killed" virus method. He believed the same approach could work for polio. While many in the scientific community, including Albert Sabin, favored a live attenuated virus, Salk pursued a dead virus approach because he believed it was safer.

The Science of the Kill

Salk’s method involved growing the three types of poliovirus, then deactivating them with formaldehyde. The formalin treatment rendered the virus completely incapable of replicating or causing disease while leaving the protein coat intact for the immune system to recognize. The challenge was ensuring that every single virus particle was killed without destroying its ability to stimulate immunity. Salk rigorously tested the vaccine on himself, his wife, and his children before moving to larger human trials. The results of these small-scale tests proved the vaccine was safe and produced a strong immune response.

The 1954 Field Trial: The Largest Medical Experiment in History

The NFIP, flush with public donations, organized what remains the largest and most publicized medical field trial in history. In 1954, nearly 1.8 million schoolchildren—dubbed the "Polio Pioneers"—participated. The trial was a randomized, controlled, double-blind study orchestrated by Dr. Thomas Francis Jr. The world waited with bated breath. On April 12, 1955—the tenth anniversary of FDR’s death—the results were announced. The Salk vaccine was safe and effective. Church bells rang, and newspapers declared a miracle. Salk, hailed as a hero, famously refused to patent the vaccine, stating, "Could you patent the sun?"

The Cutter Incident: A Setback for Safety

The euphoria was short-lived. Just weeks after the announcement, a manufacturing error at Cutter Laboratories in Berkeley, California, resulted in a batch of vaccine that contained live, virulent poliovirus. The Cutter Incident caused 40,000 cases of polio, leaving 200 children with permanent paralysis and causing 10 deaths. This tragedy was a devastating blow to public confidence, but it led to a revolution in vaccine manufacturing safety. The U.S. government established a strict system for licensing and inspecting biological products, setting a new global standard for quality control. The Salk vaccine quickly returned to the market, now manufactured under the most stringent safety protocols of the time.

Albert Sabin and the Oral Polio Vaccine (OPV)

While Salk’s vaccine dramatically reduced the incidence of polio, it had limitations. It was administered by injection, required a booster to maintain immunity, and while it protected the individual from paralysis, it did not effectively stop the virus from replicating in the gut and spreading to others. Albert Sabin, a rival of Salk, was convinced that a live, orally administered vaccine was the superior solution.

The Pursuit of the Weakened Virus

Sabin’s path was more difficult. He spent nearly a decade testing hundreds of different viral strains, systematically weakening them by passing them through non-human primate cells. The goal was to create a strain that was "attenuated"—so weak it could not cause paralysis in humans, but strong enough to replicate in the gut, stimulating a robust, lifelong immune response. Sabin had to do this for each of the three serotypes. He eventually succeeded with three stable, attenuated strains.

The Sabin Trials and Global Adoption

Interestingly, the definitive large-scale trials for the Sabin vaccine did not take place in the United States. In a remarkable collaboration born of Cold War necessity, Sabin partnered with Soviet scientists, including Dr. Mikhail Chumakov. In 1959, over 10 million children in the Soviet Union were vaccinated with the Sabin oral vaccine. The results were outstanding. The vaccine was easy to administer (drops on a sugar cube), cheap to produce, and it rapidly reduced polio cases in the USSR. These results convinced the world of the vaccine's power. By the early 1960s, the Oral Polio Vaccine (OPV) was licensed in the United States and quickly became the primary tool for fighting polio.

The Advantages of OPV

The OPV held several distinct advantages over the Salk IPV. First, it induced "gut immunity," mimicking the natural infection pathway. This meant that if a vaccinated person later encountered wild poliovirus, the virus could not replicate in their intestines. This stopped the chain of transmission. Second, because it was a live virus, it could be shed in the stool and spread to close contacts, effectively immunizing neighbors and family members—a phenomenon known as "herd immunity." This made OPV the ideal weapon for mass campaigns in developing countries.

The Global Impact: Towards Eradication

The widespread use of the Sabin vaccine, alongside the continued use of the Salk vaccine in some areas, led to the complete elimination of polio in most developed nations by the 1970s. The disease that had once been a universal fear began to fade from memory in the West. The World Health Organization (WHO) and partners set their sights on global eradication.

The Global Polio Eradication Initiative (GPEI)

In 1988, the World Health Assembly launched the Global Polio Eradication Initiative (GPEI)—a massive public health undertaking. At that time, polio was paralyzing approximately 350,000 children every year in over 125 countries. The GPEI brought together an unprecedented coalition: the WHO, Rotary International, the U.S. Centers for Disease Control and Prevention (CDC), and UNICEF. The strategy was to achieve high routine immunization coverage, supplement it with massive National Immunization Days (NIDs), and maintain active surveillance to detect the virus.

Remarkable Progress and Hurdles

The progress was staggering. By the year 2000, the number of cases had dropped by 99.9%, and polio was endemic in only a few countries. The Americas were certified polio-free in 1994, followed by the Western Pacific and Europe. However, the final fraction of a percent proved to be the hardest. The campaign faced cultural resistance, conflict that prevented vaccinators from reaching children, and the re-emergence of the virus from the vaccine itself in rare cases.

According to the WHO fact sheet on polio, the fight continues in the remaining strongholds of Afghanistan and Pakistan. The virus also continues to pose a risk in under-immunized communities via circulating vaccine-derived polioviruses (cVDPV), a rare genetic reversion of the weakened vaccine virus to a virulent form.

The Endgame Strategy and the Legacy of the Founders

The endgame for polio is a complex balancing act between maintaining the power of the OPV and eliminating the risk of cVDPV. The solution, which began in 2016, has been a phased withdrawal of the oral vaccine.

The Switch from tOPV to bOPV and the Role of IPV

For decades, the trivalent OPV (tOPV) protected against all three types of wild poliovirus. After wild type 2 was declared eradicated globally in 2015, a coordinated "switch" was made to bivalent OPV (bOPV), which protects against types 1 and 3. To maintain immunity against type 2, the GPEI introduced at least one dose of the Salk Inactivated Polio Vaccine (IPV) into the routine immunization schedules of all countries. This hybrid strategy uses the injectable Salk vaccine to prevent paralysis without the risk of vaccine-derived strains, and the oral Sabin vaccine to stop transmission in the field.

The Novel Oral Polio Vaccine (nOPV2)

In 2021, a new tool entered the arsenal: the novel oral polio vaccine type 2 (nOPV2). This was specifically designed to be more genetically stable than the traditional Sabin type 2 vaccine, making it far less likely to revert into a dangerous cVDPV. The development and rapid deployment of nOPV2 is a direct continuation of the scientific legacy of Salk and Sabin, applying modern genetic engineering to the foundational principles of vaccinology. The CDC provides extensive documentation on the evolution of these polio vaccines.

The Final Frontier

We stand on the precipice of eradicating just the second human disease in history (after smallpox). The obstacles are immense. They include geopolitical conflict, logistical hurdles in remote regions, misinformation campaigns that erode vaccine confidence, and the ongoing need for billions of dollars in funding. However, the tools to succeed exist today, derived directly from the discoveries of Salk and Sabin.

A Transformative Century

The history of the polio vaccine is not just a story of laboratory breakthroughs. It is a story of a society mobilized to save its children—a coalition of dime donations, desperate parents, dedicated scientists, and global institutions. Jonas Salk gave the world a safe, effective shield. Albert Sabin gave the world a powerful, practical sword to cut the chains of transmission. Together, they conquered one of humanity's most feared scourges in the industrialized world and built the framework for a final assault against it everywhere.

As we navigate new global health threats, the lessons of the polio fight remain as relevant as ever. The power of vaccines, the necessity of robust global health systems, and the profound impact of investing in research are all legacies of the fight against polio. The day we certify a polio-free world will be the final victory for the Polio Pioneers of 1954, the millions of vaccinators who follow in their footsteps, and the scientists who dared to imagine a world without this disease.

The successful development of these vaccines fundamentally altered the trajectory of human health and demonstrated the undeniable truth that science, applied with courage and conviction, can change the world. The end of the polio story is still being written, but the authors are clear: thanks to Salk, Sabin, and the global community, a polio-free future is within our reach.